4basebio (4BB) Competitors GBX 1,188.20 -41.80 (-3.40%) As of 06:26 AM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesInsider Trades 4BB vs. SLN, OXB, PRTC, HZD, VRP, FARN, AVCT, ARIX, BVXP, and CIRShould you be buying 4basebio stock or one of its competitors? The main competitors of 4basebio include Silence Therapeutics (SLN), Oxford Biomedica (OXB), PureTech Health (PRTC), Horizon Discovery Group plc (HZD.L) (HZD), Verona Pharma plc (VRP.L) (VRP), Faron Pharmaceuticals Oy (FARN), Avacta Group (AVCT), Arix Bioscience (ARIX), Bioventix (BVXP), and Circassia Group (CIR). These companies are all part of the "biotechnology" industry. 4basebio vs. Silence Therapeutics Oxford Biomedica PureTech Health Horizon Discovery Group plc (HZD.L) Verona Pharma plc (VRP.L) Faron Pharmaceuticals Oy Avacta Group Arix Bioscience Bioventix Circassia Group 4basebio (LON:4BB) and Silence Therapeutics (LON:SLN) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their community ranking, media sentiment, risk, institutional ownership, valuation, profitability, dividends, earnings and analyst recommendations. Does the media favor 4BB or SLN? In the previous week, 4basebio's average media sentiment score of 0.00 equaled Silence Therapeutics'average media sentiment score. Company Overall Sentiment 4basebio Neutral Silence Therapeutics Neutral Which has stronger earnings & valuation, 4BB or SLN? Silence Therapeutics has higher revenue and earnings than 4basebio. 4basebio is trading at a lower price-to-earnings ratio than Silence Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio4basebio£311K489.42-£9.84M-£0.78-1,523.33Silence Therapeutics£11.35M0.00N/A-£48.60N/A Is 4BB or SLN more profitable? Silence Therapeutics' return on equity of 0.00% beat 4basebio's return on equity.Company Net Margins Return on Equity Return on Assets 4basebioN/A -231.29% -54.30% Silence Therapeutics N/A N/A N/A Do insiders & institutionals have more ownership in 4BB or SLN? 2.0% of 4basebio shares are owned by institutional investors. 68.4% of 4basebio shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Does the MarketBeat Community believe in 4BB or SLN? Silence Therapeutics received 203 more outperform votes than 4basebio when rated by MarketBeat users. CompanyUnderperformOutperform4basebioN/AN/ASilence TherapeuticsOutperform Votes20368.81% Underperform Votes9231.19% SummarySilence Therapeutics beats 4basebio on 5 of the 8 factors compared between the two stocks. Get 4basebio News Delivered to You Automatically Sign up to receive the latest news and ratings for 4BB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart 4BB vs. The Competition Export to ExcelMetric4basebioBiotechnology IndustryMedical SectorLON ExchangeMarket Cap£152.21M£177.19M£5.39B£2.04BDividend YieldN/A3.64%5.37%5.16%P/E Ratio-1,523.33132.1388.101,926.64Price / Sales489.4219,224.331,285.40384,006.48Price / Cash16.0813.0136.6029.21Price / Book-28.989.184.953.08Net Income-£9.84M-£20.89M£117.96M£183.60M7 Day Performance-7.13%0.22%2.49%3.09%1 Month Performance1.30%2.13%3.44%3.42%1 Year Performance84.22%130.91%27.06%165.41% 4basebio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)4BB4basebioN/AGBX 1,188.20-3.4%N/A+83.9%£152.21M£311,000.00-1,523.33101News CoverageSLNSilence TherapeuticsN/AN/AN/AN/A£480.35M£11.35M-11.01100High Trading VolumeOXBOxford Biomedica0.6574 of 5 starsGBX 399-2.7%GBX 433.33+8.6%+124.0%£420.39M£97.28M-277.08891PRTCPureTech Health1.5026 of 5 starsGBX 142+1.9%GBX 455+220.4%-26.4%£339.98M£3.33M-617.39300HZDHorizon Discovery Group plc (HZD.L)N/AN/AN/AN/A£302.98M£54.63M-33.55416VRPVerona Pharma plc (VRP.L)N/AN/AN/AN/A£228MN/A-1.6822Gap UpFARNFaron Pharmaceuticals OyN/AGBX 208.50+4.3%N/A-34.5%£218.13M£-725,000.00-651.5634AVCTAvacta GroupN/AGBX 51.70-0.6%N/A-51.0%£185.24M£22.62M-574.44120ARIXArix BioscienceN/AN/AN/AN/A£183.73M£14.16M1,290.919BVXPBioventixN/AGBX 3,100-0.8%N/A-27.3%£161.82M£13.60M1,901.8412Gap DownCIRCircassia GroupN/AN/AN/AN/A£142.66M£27.90M3,400.00111Gap Down Related Companies and Tools Related Companies Silence Therapeutics Competitors Oxford Biomedica Competitors PureTech Health Competitors Horizon Discovery Group plc (HZD.L) Competitors Verona Pharma plc (VRP.L) Competitors Faron Pharmaceuticals Oy Competitors Avacta Group Competitors Arix Bioscience Competitors Bioventix Competitors Circassia Group Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (LON:4BB) was last updated on 1/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | SponsoredI was wrong. Dead wrong. Something is stirring deep in Silicon Valley. My team and I have been watching the tech markets closely. ...Porter & Company | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 4basebio PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share 4basebio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
